fludarabine + busulfan + cyclophosphamide

The drug Flu-Bu-Cy refers to a conditioning regimen used in hematopoietic stem cell transplantation (HSCT) that combines three drugs: fludarabine, busulfan, and cyclophosphamide. ## Description Flu-Bu-Cy is a conditioning regimen used before allogeneic hematopoietic stem cell transplantation. This combination therapy includes fludarabine (an immunosuppressive agent), busulfan (an alkylating agent), and cyclophosphamide (another alkylating agent). The regimen is designed to provide sufficient immunosuppression and anti-leukemic activity while potentially reducing certain toxicities compared to traditional regimens like Bu-Cy alone[1][3]. ## Administration The drugs in this regimen are typically administered intravenously. Fludarabine and busulfan are often given once daily, while cyclophosphamide may be administered on specific days of the conditioning schedule[1][2]. ## Clinical Use This conditioning regimen is primarily used for patients with hematologic malignancies undergoing allogeneic stem cell transplantation. Studies have compared various conditioning regimens including Flu-Bu, Bu-Cy, and Flu-Bu-Cy to determine optimal outcomes in terms of toxicity profiles, non-relapse mortality, and overall survival[1][3][5]. ## Toxicity Profile The toxicity profile of Flu-Bu-Cy differs from other conditioning regimens. Compared to Bu-Cy alone, fludarabine-containing regimens may have lower rates of certain toxicities: - Lower risk of sinusoidal obstruction syndrome (formerly called veno-occlusive disease) - Potentially reduced treatment-related mortality - Different patterns of mucositis and renal toxicity depending on the specific regimen and prophylaxis used[1][2][4] ## Comparative Efficacy Studies have shown that fludarabine-based regimens (including Flu-Bu-Cy) may offer advantages over traditional Bu-Cy regimens: - Lower treatment-related mortality - Reduced risk of acute graft-versus-host disease - Comparable or improved overall survival and progression-free survival in certain patient populations[1][3] The specific ordering of the drugs in the regimen (e.g., Cy followed by Bu versus Bu followed by Cy) may also impact outcomes and toxicity profiles[2][5].

Other names

FluBuCy